

2018 3RD QUARTER RECAP

Dear Colleagues,

This issue of *POINT-ers* is bittersweet for us, as it is the last quarterly newsletter for the trial.

We continue to make progress on closeout activities and secondary publications from POINT. Proposals for manuscripts are trickling in, as are acceptances for poster and oral presentations at various meetings in the upcoming months.

To date, nearly half of the sites that participated in the trial have completed regulatory closeout. Please continue to reach out to your corresponding study manager or CRA should you need additional materials to continue the local closeout process. We are working diligently to close all sites by December 2018.

Call for Proposals

As we shared in our previous newsletter, the POINT Publications Policy v4.0 is available in the Toolbox on the NETT Website under POINT (see link below). If you would like to submit a manuscript proposal for review by the POINT Executive Committee, please read the submission guidelines and complete the POINT Trial Manuscript Proposal Form found in Appendix A of the policy.

The completed form can be submitted to mary.farrant2@ucsf.edu or POINTOperations@ucsf.edu.

POINT Publications Policy and Appendix A
NETT.UMich.edu >> [POINT](#) >> [Toolbox](#) >>
[End of Study Documents](#)

Manuscripts in Development

- Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared with Aspirin alone after TIA or Minor Ischemic Stroke in the POINT Trial
- Time Course of Risk versus Benefit of Clopidogrel and Aspirin in Acute Minor Ischemic Stroke and High-Risk TIA
- Effects of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
- Clopidogrel Pharmacogenetics in the POINT Trial
- Cost Utility Analysis in POINT

As mentioned on several occasions, we couldn't have completed this important trial without you. Thank you for your efforts over the last 8 years.

Sincerely,

Clay Johnston MD, PhD, POINT Principal Investigator

Don Easton MD, POINT co-Principal Investigator

Anthony S. Kim MD, MAS, POINT co-Principal Investigator

**IN THIS ISSUE: POINT TRIAL PROPOSAL
REVIEW PROCESS**

POINT at the WSC 2018 Montreal, Canada

The POINT Investigators will be giving two oral presentations at the World Stroke Congress (WSC) in Montreal, Canada from 17-20 October 2018 at the Palais des Congrès. Details to follow. We hope to see you there!

POINT at the ISC 2019 Honolulu, Hawaii

Secondary analyses from POINT will also be presented at the International Stroke Conference (ISC) in Honolulu, Hawaii from 6-8 February 2019. We will share more details as the date approaches.

POINT TRIAL PROPOSAL REVIEW PROCESS

1. Complete POINT Trial Manuscript Proposal Form (Appendix A) and submit via email to POINT Executive Committee for review at POINTOperations@ucsf.edu.
2. The Executive Committee reviews request and within 90 calendar days approves, modifies or disapproves the request using the POINT Manuscript Proposal Review Form (Appendix B). More detailed information may be requested from the authors.
3. The final version of the completed abstract, poster, slides and/or manuscript must be sent to the POINT Executive Committee for review at least 6 weeks prior to the submission deadline or presentation date; for manuscripts, the submission cover letter must be included with the copy of the manuscript.
4. The Executive Committee approves, approves with modification or disapproves the abstract, poster, slides or manuscript (Appendix C).
5. If the manuscript is denied, feedback is given within 2 weeks of the denial, detailing the rationale for disapproval. If changes are recommended, the revised version is submitted to the Executive Committee prior to submitting the manuscript or abstract for publication.
6. The Executive Committee is kept informed about acceptances, rejections or resubmissions of materials; if a manuscript is changed for resubmission, it should be submitted to Executive Committee for re-approval prior to being submitted for publication.
7. The Executive Committee reserves the right to make final determinations in conflicts or disputes about authorship ranking.